BTK and mantle cell lymphoma: Similar results were seen with another selective BTK inhibitor, zanubrutinib, which received accelerated FDA approval based on the impressive results from phase II and phase I/II clinical trials yielding ORR of 84% (CR 59% and PR 24%) in relapsed MCL previously treated with one line therapy.72, 86